TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03314922
Drug: Parsaclisib
Normalized name: Parsaclisib
DrugBank: Parsaclisib (DB14867)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Parsaclisib administered orally once daily for 8 weeks at the protocol-defined dose, followed by a once-weekly regimen at the same dose.
Study: NCT00748904
Drug: Rifaximin
Normalized name: Rifaximin
DrugBank: Rifaximin (DB01220)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 400 mg orally
Study: NCT00748904
Drug: Lactulose
Normalized name: Lactulose
DrugBank: Lactulose (DB00581)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 20 grams titrate to 2-3 bowel movements in one day
Study: NCT01013103
Drug: Atorvastatin, high vs low dose
DrugBank: Atorvastatin (DB01076)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: In this arm patients with ischemic heart disease will be recruited. In a double-blind crossover design heart failure patients (n=30) naïve to statins treatment will be randomized to receive oral atorvastatin 10mg/day 1x1(n=15) or oral atorvastatin 40mg/day 1x1 (n=15) for 4 weeks. At the end of 4 weeks a 2-week wash out period will follow and then all patients will switch atorvastatin dose and continue treatment for 4 weeks (e.g all patients that were under atorvastatin 10mg/day will be switched to atorvastatin 40mg/day and vice versa).
Study: NCT01013103
Drug: Atorvastatin vs Placebo
DrugBank: Atorvastatin (DB01076)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: In this arm, patients undergoing cardiac surgery (CABG, valve replacement or aortic surgery) that are not under statins treatment will be recruited. Patients will be randomized in a double-blind fashion to atorvastatin 40mg/day or placebo for 3 days before surgery date.
Study: NCT01124500
Drug: methylphenidate via transdermal patch compared to placebo
Normalized name: methylphenidate Transdermal System
DrugBank: Methylphenidate (DB00422)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The participants will start with a 10mg MPH patch on day -4, the 1st day of the titration period. This will be increased up to 20mg over 4-day titration period as needed and tolerated, and continued on the optimal dose. Subjects will be seen on day 1 of the double-blind part of the study at a patient education room or the Dr.'s office and receive 10 identical patches including 5 MPH and 5 placebo patches that will be randomly assigned over the 10-day course. The patch will be placed at 9am and removed at 4pm daily for 10 days. During the 10 days, each subject will be monitored for continuous 240 hours by actigraphy based activity monitors to follow activity levels and energy expenditure.
Study: NCT04380519
Drug: RPH-104 80 mg
Normalized name: RPH-104
DrugBank: Goflikicept (DB16396)
Approvals — FDA: no, EMA: no, PMDA: no
Description: solution for subcutaneous administration 40 mg/mL, 2 mL in the 4-mL glass vial
Study: NCT04380519
Drug: Olokizumab 64 mg
Normalized name: olokizumab
DrugBank: Olokizumab (DB13127)
Approvals — FDA: no, EMA: no, PMDA: no
Description: solution for subcutaneous administration 160 mg/mL, in the 2-mL glass vial (target volume 0,4 ml)
Study: NCT01068600
Drug: Indacaterol
Normalized name: Indacaterol
DrugBank: Indacaterol (DB05039)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Once daily via single-dose dry powder inhaler (SDDPI)
Study: NCT01068600
Drug: Placebo to indacaterol
DrugBank: Indacaterol (DB05039)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Once daily via SDDPI
Study: NCT04173494
Drug: Momelotinib
Normalized name: MOMELOTINIB
DrugBank: Momelotinib (DB11763)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Momelotinib tablets will be self-administered orally once daily
Study: NCT04173494
Drug: Placebo to match danazol
Normalized name: Danazol
DrugBank: Danazol (DB01406)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Danazol placebo capsules will be self-administered orally twice daily
Study: NCT04173494
Drug: Danazol
Normalized name: Danazol
DrugBank: Danazol (DB01406)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Danazol capsules will be self-administered orally twice daily
Study: NCT04173494
Drug: Placebo to match momelotinib
Normalized name: momelotinib
DrugBank: Momelotinib (DB11763)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Momelotinib placebo tablets will be self-administered orally once daily
Study: NCT00635219
Drug: Vortioxetine (Lu AA21004)
Normalized name: Vortioxétine
DrugBank: Vortioxetine (DB09068)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 2.5 mg/day; encapsulated tablets; orally
Study: NCT00635219
Drug: Vortioxetine (Lu AA21004)
Normalized name: Vortioxétine
DrugBank: Vortioxetine (DB09068)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 5 mg/day; encapsulated tablets; orally
Study: NCT00635219
Drug: Vortioxetine (Lu AA21004)
Normalized name: Vortioxétine
DrugBank: Vortioxetine (DB09068)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 10 mg/day; encapsulated tablets; orally
Study: NCT00635219
Drug: Duloxetine
Normalized name: Duloxetine
DrugBank: Duloxetine (DB00476)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 60 mg/day; encapsulated capsules; orally
Study: NCT01191762
Drug: sevelamer carbonate
Normalized name: Sevelamer Carbonate
DrugBank: Sevelamer (DB00658)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 2400 mg with each meal for 4 weeks
Study: NCT00984997
Drug: Cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 50 mg/M\^2 given intravenously on days 1 and 8; the cycle will be repeated beginning on day 29.
Study: NCT00984997
Drug: Etoposide
Normalized name: Etoposide
DrugBank: Etoposide (DB00773)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: given by mouth 30-60 minutes prior to each administration of radiotherapy, on days 1-5 and days 8-12; the cycle will be repeated beginning day 29.
Study: NCT02238080
Drug: Methoxy Polyethylene Glycol-Epoetin Beta
Normalized name: Methoxy polyethylene glycol-epoetin beta
DrugBank: Methoxy polyethylene glycol-epoetin beta (DB09107)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Methoxy polyethylene glycol-epoetin beta will be administered according to the usual standard of care and current best practice guidelines and will be observed during the study period.
Study: NCT03331640
Drug: OFF
Normalized name: Coffee
DrugBank: Arabica coffee bean (DB10666)
Approvals — FDA: no, EMA: no, PMDA: no
Description: OFF:~5-FU 2000 mg/m2 as 24 hour infusion + Na folinic acid 200 mg/m2 on D1, 8, 15, 22 Oxaliplatin 85 mg/m2 on D8, 22 3 weeks rest after D22; Cycle q42d
Study: NCT02364635
Drug: icosabutate
Normalized name: Icosabutate
DrugBank: Icosabutate (DB12990)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose at each dose levet
Study: NCT00280384
Drug: E2014 (Botulinum toxin type B)
Normalized name: botulinum toxin type B
DrugBank: Botulinum toxin type B (DB00042)
Approvals — FDA: no, EMA: no, PMDA: no
Description: A single-dose injection solution containing 20 units (U), 100 U, or 500 U/ 0.2 milliliters (mL) of E2014 was administered to extensor digitorum brevis (EDB) muscle in the left lower limb to Japanese and Caucasian participants. Duration of treatment lasted for 12 weeks: from Day -1 to Week 12. Participants were hospitalized from a day before study treatment to Day 8 for 9 nights and 10 days, and visited at the medical institution on Days 10 and 14, and Weeks 4 and 12.
Study: NCT00280384
Drug: E2014 (Botulinum toxin type B) Placebo
Normalized name: botulinum toxin type B
DrugBank: Botulinum toxin type B (DB00042)
Approvals — FDA: no, EMA: no, PMDA: no
Description: A single-dose injection solution of E2014 Placebo was administered to extensor digitorum brevis (EDB) muscle in the left lower limb to Japanese and Caucasian participants. Duration of treatment lasted for 12 weeks: from Day -1 to Week 12. Participants were hospitalized from a day before study treatment to Day 8 for 9 nights and 10 days, and visited at the medical institution on Days 10 and 14, and Weeks 4 and 12.
Study: NCT00426452
Drug: Vatalinib
Normalized name: Vatalinib
DrugBank: Vatalanib (DB04879)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02340117
Drug: nab-paclitaxel
Normalized name: NAB-PACLITAXEL COMPONENT PACLITAXEL
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: The dose of nab-paclitaxel will be 125 mg/m² and will be administered once weekly (day 3) in weeks 1, 2, 3, 5, 6 and 7. If increased toxicities related to administration of nab-paclitaxel is observed, the dose of nab-paclitaxel can be reduced to 100 or 75 mg/m² when appropriate.
Study: NCT01617746
Drug: Ambrisentan
Normalized name: Ambrisentan
DrugBank: Ambrisentan (DB06403)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 5mg od two weeks
Study: NCT01617746
Drug: Bosentan
Normalized name: Bosentan
DrugBank: Bosentan (DB00559)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 62.5mg bd two weeks
Study: NCT00148707
Drug: CT-2103 (Xyotax)
Normalized name: CT-179
DrugBank: CT-179 (DB17114)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00192634
Drug: Emtricitabine 200mg - Tenofovir 300mg
Normalized name: emtricitabine
DrugBank: Emtricitabine (DB00879)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 1 tablet once daily for 96 weeks
Study: NCT00192634
Drug: Abacavir 600mg - Lamivudine 300mg
Normalized name: abacavir 600 MG / lamivudine 300 MG [Epzicom]
DrugBank: Lamivudine (DB00709)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 1 tablet once daily for 96 weeks
Study: NCT03144934
Drug: GX-I7
Normalized name: zinc pyrithione
DrugBank: Pyrithione (DB06815)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interleukin-7 (IL-7) is T cell growth factor that can be used for treating lymphopenia patients. GX-I7 is a protein drug recombining human IL-7 and hybrid Fc (hyFc). HyFc made by Genexine is composed of hinge-CH2 region of Immunoglobulin D (IgD) and CH2-CH3 region of Immunoglobulin G4 (IgG4). The recombined region is not exposed and each region's characteristics can reduce immunogenicity and improve the efficacy of drug. Consequently, it will be able to treat the patients with lymphopenia in effective ways.
Study: NCT02543060
Drug: stannous fluoride toothpaste
Normalized name: stannous fluoride Toothpaste
DrugBank: Stannous fluoride (DB11092)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 0.454% stannous fluoride toothpaste
Study: NCT02340117
Drug: Gemcitabine
Normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: The dose of gemcitabine will be 1000 mg/m² and will be administered once weekly (day 3) in weeks 1, 2, 3, 5, 6 and 7, after the administration of nab-paclitaxel. If increased toxicities related to administration of gemcitabine is observed, the dose of gemcitabine can be reduced to 800 or 600 mg/m² when appropriate.
Study: NCT00382499
Drug: Lidocaine Intravenous Infusion
Normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 1.5 mg/kg IV bolus on induction, 3 mg/kg/hr infusion from inducation until fascia closure
Study: NCT03241147
Drug: Lu AF35700
Normalized name: Lu-DOTA-TATE
DrugBank: Lutetium Lu 177 dotatate (DB13985)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose, 10 mg film coated tablet
Study: NCT04662515
Drug: Dabigatran
Normalized name: Dabigatran
DrugBank: Dabigatran (DB14726)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04662515
Drug: Rivaroxaban
Normalized name: Rivaroxaban
DrugBank: Rivaroxaban (DB06228)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT04662515
Drug: Apixaban
Normalized name: Apixaban
DrugBank: Apixaban (DB06605)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT04662515
Drug: Edoxaban
Normalized name: Edoxaban
DrugBank: Edoxaban (DB09075)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT04662515
Drug: Warfarin
Normalized name: Warfarin
DrugBank: Warfarin (DB00682)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT04521049
Drug: Saxagliptin 5mg
Normalized name: Saxagliptin 5mg Oral tablet
DrugBank: Saxagliptin (DB06335)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients would be assigned to saxagliptin (Onglyza® AstraZeneca Pharmaceuticals LP, Indiana, USA), either received a dose of 5 mg or 2.5 mg daily if patients had eGFR \<50 mL/min/1.73 m2
Study: NCT01934777
Drug: placebo pearls
DrugBank: Pear (DB10554)
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo
Study: NCT00524901
Drug: Epoetin alpha
Normalized name: Epoetin
DrugBank: Erythropoietin (DB00016)
Approvals — FDA: no, EMA: no, PMDA: no
Description: A single dose of epoetin alpha during CABG for three vessel disease, 60.000 IU intravenously.
Study: NCT00466596
Drug: Gamma Tocopherol
Normalized name: Gamma tocopherol
DrugBank: Tocopherol (DB11251)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 14 days of daily high dose (1200mg) Gamma Tocopherol. Subjects will receive a 14 day supply (28 softgel capsules, approximately 600 grams of gT each) dispensed by the University of North Carolina Hospitals Investigational Drug Service and provided by YASOO Medical.
Study: NCT03682211
Drug: Morphine sulphate
Normalized name: Morphine sulphate
DrugBank: Morphine (DB00295)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 10 mg/ml Morphine sulphate BP (Antigen Pharmaceuticals, Marketing Authorisation No.PA 73/20/1) administered intravenously.
Study: NCT02954172
Drug: Bevacizumab in Combination With Paclitaxel/Carboplatin
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Drug Bevacizumab15mg/kg in combination with Paclitaxel/Carboplatin 6 cycles then maintains at 7.5 mg/kg
Study: NCT02954172
Drug: IBI305 in Combination with Paclitaxel/Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Drug IBI305 15mg/kg in combination with Paclitaxel/Carboplatin 6 cycles then maintains at 7.5 mg/kg
Study: NCT01519167
Drug: Dexmedetomidine
Normalized name: Dexmedetomidine
DrugBank: Dexmedetomidine (DB00633)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 0.1 - 1.0 mcg/kg/hr IV
Study: NCT01519167
Drug: Midazolam
Normalized name: Midazolam
DrugBank: Midazolam (DB00683)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 0.025 - 2 mg/kg IV
Study: NCT00853567
Drug: Proellex
Normalized name: guaiacolsulfonate / hydrocodone bitartrate Oral Solution [Prolex DH]
DrugBank: Telapristone acetate (DB05253)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25 mg oral daily dose vs. 50 mg oral daily dose vs. placebo
Study: NCT00275548
Drug: Pegasys
Normalized name: Pegasys
DrugBank: Peginterferon alfa-2a (DB00008)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 135-180 micrograms administered sc once weekly
Study: NCT00275548
Drug: Copegus
Normalized name: Copegus
DrugBank: Ribavirin (DB00811)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 400-1200 mg/day for 48 weeks
Study: NCT00782834
Drug: Nilotinib
Normalized name: Nilotinib
DrugBank: Nilotinib (DB04868)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 400 mg orally twice daily until disease progression, intolerability or withdrawal of consent
Study: NCT02452515
Drug: BAY1142524
Normalized name: BAY1142524
DrugBank: Fulacimstat (DB15085)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg BAY1142524 or placebo given as 5 mg IR tablet twice daily for 2 weeks
Study: NCT02452515
Drug: BAY1142524
Normalized name: BAY1142524
DrugBank: Fulacimstat (DB15085)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg BAY1142524 or placebo given as 2 x 5 mg IR tablets twice daily as for 2 weeks
Study: NCT02452515
Drug: BAY1142524
Normalized name: BAY1142524
DrugBank: Fulacimstat (DB15085)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25 mg BAY1142524 or placebo given as 5 x 5 mg IR tablets twice daily for 2 weeks
Study: NCT02452515
Drug: BAY1142524
Normalized name: BAY1142524
DrugBank: Fulacimstat (DB15085)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg BAY1142524 or placebo given 1 x 50 mg IR tablet once daily for 2 weeks
Study: NCT00158496
Drug: pegylated interferon alpha2a
Normalized name: Pegylated interferon alpha-2a
DrugBank: Peginterferon alfa-2a (DB00008)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00158496
Drug: ribavirin
Normalized name: Ribavirin
DrugBank: Ribavirin (DB00811)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT04059588
Drug: 2141 V-11
Normalized name: Penicillin V
DrugBank: Phenoxymethylpenicillin (DB00417)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: intratumoral injection of 2141-V11
Study: NCT03241719
Drug: IL-2
Normalized name: IL-2
DrugBank: Human interleukin-2 (DB14865)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will receive vascularized composite allotransplantation (e.g. facial, hand and/or abdominal wall transplants) under conventional immune suppression. No sooner than 3 months after VCA, subjects will receive a protocol of daily recombinant IL-2 at low doses for 8 weeks.
Study: NCT01955629
Drug: Aflibercept AVE0005
Normalized name: Aflibercept
DrugBank: Aflibercept (DB08885)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Pharmaceutical form: Concentrate for solution for infusion; Route of administration: Intravenous
Study: NCT01955629
Drug: Oxaliplatin
Normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Pharmaceutical form: Concentrate for solution for infusion; Route of administration: Intravenous
Study: NCT02562664
Drug: CC
Normalized name: CC
DrugBank: Cholecalciferol (DB00169)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg clomiphene Citrate (Clomid , global Napi , Egypt) CC tablets taken from day 3 to day 7 of the cycle
Study: NCT02562664
Drug: Metformin
Normalized name: Metformin
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: wMetformin (Cidophage , Amon , Egypt) 500 mg twice daily continuously for three cycles.
Study: NCT02677519
Drug: Aptensio XR
Normalized name: Aptensio XR
DrugBank: Methylphenidate (DB00422)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Orally-administered extended release formulation of methylphenidate; once daily dosing
Study: NCT02259088
Drug: Ranibizumab (RFB002)
Normalized name: Ranibizumab
DrugBank: Ranibizumab (DB01270)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Ranibizumab 0.5 mg/0.05 mL for intravitreal injection
Study: NCT02259088
Drug: Sham injection
Normalized name: BLACK BEAN ANTI HAIR LOSS SHAM POO SET KIT
DrugBank: Bean (DB14709)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Imitation of an intravitreal injection consisting of an empty vial and an injection syringe without a needle
Study: NCT00571168
Drug: Emend
Normalized name: Emend
DrugBank: Aprepitant (DB00673)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 125 mg/d on day 1; 80 mg/d on day 2-4
Study: NCT03753113
Drug: Topical Herbal Solution
Normalized name: Hyperici herba
DrugBank: St. John's Wort (DB01323)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Use Topical Herbal Solution every day in scalp hair loss areas for 36 weeks.
Study: NCT03753113
Drug: Topical Minoxidil 5%
DrugBank: Minoxidil (DB00350)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Use Minoxidil 5% solution every day in scalp hair loss areas for 36 weeks.
Study: NCT02659397
Drug: ETC-1002
Normalized name: benzalkonium
DrugBank: Benzalkonium (DB11105)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Blinded ETC-1002 180 mg tablet once daily for 4 weeks (Weeks 1 to 4)
Study: NCT02659397
Drug: Atorvastatin
Normalized name: Atorvastatin
DrugBank: Atorvastatin (DB01076)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Atorvastatin 80 mg tablet once daily for 8 weeks (Weeks -4 to 4)
Study: NCT01033448
Drug: COPEGUS
Normalized name: Copegus
DrugBank: Ribavirin (DB00811)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: COPEGUS 800 mg or 1000-1200 mg po for 24 weeks
Study: NCT01033448
Drug: peginterferon alfa-2a [Pegasys]
DrugBank: Peginterferon alfa-2a (DB00008)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: PEGASYS 180 micrograms sc once weekly for 24 weeks
Study: NCT02709382
Drug: Cefepime and Tazobactam combination
Normalized name: cefepime and amikacin
DrugBank: Cefepime (DB01413)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00339001
Drug: erythropoietin and early iron supplements
DrugBank: Erythropoietin (DB00016)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03617224
Drug: TSEBT and pembrolizumab
DrugBank: Pembrolizumab (DB09037)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Dose regimens are sequential therapy of TSEBT with Pembrolizumab.
Study: NCT02613026
Drug: Pirarubicin
Normalized name: pirarubicin
DrugBank: Pirarubicin (DB11616)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02613026
Drug: Docetaxel
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02744040
Drug: ART initiation at time of HIV diagnosis
Normalized name: rose bengal AT
DrugBank: Rose bengal (DB11182)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Immediate ART initiation
Study: NCT02744040
Drug: ART at 24 weeks
Normalized name: AT-III
DrugBank: Antithrombin III human (DB11598)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ART initiation 24 weeks after enrollment
Study: NCT01646489
Drug: Miravirsen sodium
Normalized name: Miravirsen
DrugBank: Miravirsen (DB12851)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Miravirsen 7 mg/kg to be administered as single subcutaneous injections for a total of 5 doses over a 5 week treatment period.
Study: NCT01646489
Drug: Telaprevir
Normalized name: Telaprevir
DrugBank: Telaprevir (DB05521)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Telaprevir 750 mg to be administered as single and multiple oral doses over two 7 day treatment periods.
Study: NCT03208985
Drug: Use Phase (Ulipristal Acetate, 30 mg)
Normalized name: ulipristal acetate 30 MG
DrugBank: Ulipristal (DB08867)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: All subjects enrolled in the use phase of this open-label study will be given the opportunity to purchase and take 30 mg of ulipristal acetate.~Subjects are to use the investigational product based on their understanding of the directions on the outer packaging including Drug Facts Label and inside the product packaging (in the Consumer Information Leaflet).
Study: NCT03822559
Drug: A preservative-free, a clear, colorless sterile aqueous ophthalmic solution containing 0.015mg of tafluprost and 5.0mg of timolol in 1mL
DrugBank: Timolol (DB00373)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: One drop a time, once daily administration of DE-111A eye drops in the affected eye(s) at 8:00 am (±1h) for 3 months.
Study: NCT03822559
Drug: A preservative-free, a clear, colorless sterile aqueous ophthalmic solution containing 0.015mg of tafluprost in 1mL
DrugBank: Tafluprost (DB08819)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: One drop a time, once daily administration of preservative-free 0.0015% tafluprost eye drops in the affected eye(s) at 8:00 (±1h) for 3 months.
Study: NCT03859362
Drug: Ertapenem Injection
Normalized name: ertapenem Injection
DrugBank: Ertapenem (DB00303)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 1 g of ertapenem q24h, 30 min infusion
Study: NCT03323567
Drug: Lidocaine 2% Injectable Solution
Normalized name: lidocaine 2% injectable solution
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: intramuscular Lidocaine 2% injection
Study: NCT00310661
Drug: Sarizotan
Normalized name: Sarizotan
DrugBank: Sarizotan (DB06454)
Approvals — FDA: no, EMA: no, PMDA: no
Description: The dose of sariztan HCI for each patient in the drug arm will be given 2mg b.i.d. orally during the first 4 weeks of treatment. If efficacy is inadequate and there are no safety concerns, the option to raise the dose to 5mg b.i.d is given. After 8 weeks of treatment, the option to raise the dose to 7mg bid is given. Dose may remain the same or may be decreased again to the previous dose.